Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with QS21 may cause a stronger immune response and kill more tumor cells.
PURPOSE: This clinical trial is studying the side effects and how well giving vaccine therapy together with QS21 works in treating patients with metastatic breast cancer.
| Condition | Intervention |
|---|---|
|
Breast Cancer |
Biological: QS21 Biological: sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine Other: immunoenzyme technique Other: immunologic technique Other: laboratory biomarker analysis |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Pilot Study of Immunization of High Risk Breast Cancer Patients With a Sialyl Lewisª -Keyhole Limpet Hemocyanin Conjugate Plus the Immunological Adjuvant QS-21 |
- Safety [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
- Immune response [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- Presence of circulating tumor cells [ Time Frame: 2 years ] [ Designated as safety issue: No ]
| Enrollment: | 7 |
| Study Start Date: | March 2007 |
| Estimated Study Completion Date: | March 2014 |
| Estimated Primary Completion Date: | March 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Vaccine Therapy and QS21
Patients receive sialyl Lewisª -keyhole limpet hemocyanin conjugate vaccine subcutaneously (SC) and QS21 immunoadjuvant SC once in weeks 1, 2, 3, 7, and 19 in the absence of disease progression or unacceptable disease. Blood samples are collected periodically and evaluated for circulating tumor cells and reactivity against sialyl Lewisª antigen in ELISA and/or immunoprecipitation-western blot assays. After completion of study treatment, patients are followed every 3 months |
Biological: QS21 Biological: sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine Other: immunoenzyme technique Other: immunologic technique Other: laboratory biomarker analysis |
Detailed Description:
OBJECTIVES:
Primary
- Determine the safety of sialyl Lewisª -keyhole limpet hemocyanin conjugate vaccine and QS21 immunoadjuvant in patients with metastatic breast cancer.
- Determine the IgG and IgM antibody response to this regimen in these patients.
- Determine the proportion of breast cancer cells expressing this antigen in these patients.
Secondary
- Monitor the presence of circulating tumor cells prior to, during, and after this regimen in these patients.
OUTLINE: Patients receive sialyl Lewisª -keyhole limpet hemocyanin conjugate vaccine subcutaneously (SC) and QS21 immunoadjuvant SC once in weeks 1, 2, 3, 7, and 19 in the absence of disease progression or unacceptable disease.
Blood samples are collected periodically and evaluated for circulating tumor cells and reactivity against sialyl Lewisª antigen in ELISA and/or immunoprecipitation-western blot assays.
After completion of study treatment, patients are followed every 3 months.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed stage IV breast cancer meeting 1 of the following criteria:
- No evidence of disease
Stable disease on hormonal therapy
- Stable disease must be present for ≥ 2 months and include < 30% decrease or < 20% increase in the sum of the longest diameter of target lesion
- No new target lesions or unequivocal progression of non-target lesions
- Elevation in the CA 153 (BR2729) or CEA values allowed
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Female or male
- Menopausal status not specified
- Karnofsky performance status 80-100%
- Lymphocyte count ≥ 500/mm³
- WBC ≥ 3,000/mm³
- Creatinine ≤ 1.5 times upper limit of normal (ULN)
- AST ≤ 1.5 times ULN
- Alkaline phosphatase ≤ 1.5 times ULN
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No history of allergy to seafood
- No NYHA class III-IV cardiac disease
- No other active cancers except basal cell or squamous cell carcinoma of the skin
- No active infection requiring antibiotic treatment
- No known history of immunodeficiency or autoimmune disease
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- At least 4 weeks since prior chemotherapy
- At least 4 weeks since prior radiotherapy
- At least 4 weeks since prior surgery
- At least 6 weeks since prior immunotherapy
- No prior sialyl Lewisª antigen
- No concurrent immunosuppressive medications (i.e., corticosteroids)
- Concurrent hormonal therapy allowed
Contacts and Locations| United States, New York | |
| Memorial Sloan-Kettering Cancer Center | |
| New York, New York, United States, 10065 | |
| Principal Investigator: | Teresa Ann Gilewski, MD | Memorial Sloan-Kettering Cancer Center |
| Principal Investigator: | Maura N. Dickler, MD | Memorial Sloan-Kettering Cancer Center |
More Information
Additional Information:
No publications provided
| Responsible Party: | Memorial Sloan-Kettering Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00470574 History of Changes |
| Other Study ID Numbers: | 06-156, P30CA008748, MSKCC-06156 |
| Study First Received: | May 3, 2007 |
| Last Updated: | March 15, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Memorial Sloan-Kettering Cancer Center:
|
recurrent breast cancer stage IV breast cancer male breast cancer |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Adjuvants, Immunologic |
Keyhole-limpet hemocyanin QS 21 Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 16, 2013